Prognostic variables in node-negative and node-positive breast cancer
Editat de Giampietro Gasparinien Limba Engleză Paperback – 7 oct 2012
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1332.91 lei 38-44 zile | |
Springer Us – 7 oct 2012 | 1332.91 lei 38-44 zile | |
Hardback (1) | 1365.89 lei 38-44 zile | |
Springer Us – 27 feb 1999 | 1365.89 lei 38-44 zile |
Preț: 1332.91 lei
Preț vechi: 1403.06 lei
-5% Nou
Puncte Express: 1999
Preț estimativ în valută:
255.12€ • 265.90$ • 212.37£
255.12€ • 265.90$ • 212.37£
Carte tipărită la comandă
Livrare economică 03-09 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781461373667
ISBN-10: 1461373662
Pagini: 440
Ilustrații: VI, 428 p.
Dimensiuni: 195 x 260 x 23 mm
Greutate: 0.92 kg
Ediția:1998
Editura: Springer Us
Colecția Springer
Locul publicării:New York, NY, United States
ISBN-10: 1461373662
Pagini: 440
Ilustrații: VI, 428 p.
Dimensiuni: 195 x 260 x 23 mm
Greutate: 0.92 kg
Ediția:1998
Editura: Springer Us
Colecția Springer
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
Prognostic variables in node-negative and node-positive breast cancer - Introduction; G. Gasparini. Routinely available indicators of prognosis in breast cancer; D.L. Page, et al. Prognostic factors for patients with breast cancers 1cm and smaller; Y.-Y. Chen, S.J. Schnitt. Steroid hormone receptors in breast cancer management; C.K. Osborne. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer; J. Bryant, et al. S-phase fraction and breast cancer - a decade of experience; C.R. Wenger, G.M. Clark. Prognostic and predictive value of thymidine labelling index in breast cancer; D. Amadori, R. Silvestrini. Cyclin D1 in breast cancer; D.M. Barnes, C.E. Gillett. Cyclins and breast cancer; P.S. Steeg, Q. Zhou. Prognostic implications of expression of the cell cycle inhibitor p27Kip1; S. Cariou, et al. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer; W.J. Gullick, R. Srinivasan. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients; S. De Placido, et al. HER-2/neu as a predictive marker of response to breast cancer therapy; M.D. Pegram, et al. Prognostic and predictive value of p53 and p21 in breast cancer; R.M. Elledge. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer; R.W. Stephens, et al. Metalloproteinases and tissue inhibitors of metalloproteinases; M. Toi, et al. Matrix metalloproteinase inhibitors; P.D. Brown. The 67 kDa laminin receptor as a prognostic factor in human cancer; S. Ménard, et al. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis; R. Heimann, et al.Clinical significance of angiogenic factors in breast cancer; N. Locopo. Insulin-like growth factors in human breast cancer; M.J. Ellis, et al. Molecular prognostic markers in breast cancer; R. Dahiya, G. Deng. Prognostic significance of micrometastatic bone marrow involvement; S. Braun, K. Pantel. Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis; I. Jatoi. Time-dependence of hazard ratios for prognostic factors in primary breast cancer; S.G. Hilsenbeck, et al. Circulating tumors markers in breast cancer. Accepted utilities and novel prospects; V. Stearns, et al. The relationship between prognostic and predictive factors in the management of breast cancer; I.C. Henderson, A.J. Patek. Methodological challenges in the evaluation of prognostic factors in breast cancer; D.G. Altman, G.H. Lyman. Assessing the clinical impact of prognostic factors: When is `statistically significant' clinically useful? D.F. Hayes, et al. Prognostic variables in node-negative and node-positive breast cancer &endash; editorial; G. Gasparini. Author index. Subject index.